Skip to content

Study · Animal study (in vivo) · callithrix jacchus · 2026

5 results

ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus).

Cadena SM, Bogdanovich S, Khurana TS, Pullen A, Pearsall RS, Curran E, Faucette R, Lane J, Seehra J, Lachey JL, Mizener AD, Pistilli EE

PloS one13 Feb 2026Cited by 1 (Europe PMC)

PMID41686840 (opens in a new tab)PMCIDPMC12904423 (opens in a new tab)DOI10.1371/journal.pone.0342666 (opens in a new tab)PepBankPUB-41686840
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Pharmacological blockade of ligands for the activin receptor type IIB (ActRIIB) e.g., myostatin and activin A is associated with improvements in murine skeletal muscle mass and function. The efficacy of a similar treatment approach in a non-human primate (NHP) model would suggest a greater likelihood of success in the treatment of humans suffering from chronic myopathies. In the present study, we elucidate the potential therapeutic benefit of ACE-031, a therapeutic protein consisting of the ActRIIB extracellular region fused to human IgG1, in the common marmoset (Callithrix jacchus). Marmosets were randomized to receive ACE-031 or vehicle control (10 mM Tris buffered saline; TBS) for 14 weeks. Body composition was measured weekly throughout the experimental period and morphometric analysis and contractile properties of skeletal muscle were assessed terminally. There was a significant main effect of time and time x treatment interaction for lean body mass, such that marmosets administered ACE-031 were greater at euthanasia compared to baseline; this was not observed in the vehicle-treated controls. Biceps brachii exhibited a significant increase in the cross-sectional area of both type I and type II fibers and ex vivo contractile properties of the EDL showed an increase in absolute and specific force production. The efficacy of ACE-031 in non-human primates provides optimism that a therapeutic strategy that targets multiple negative regulators of skeletal muscle may be beneficial in treating myopathies in humans.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In marmosets, ACE‑031 increased lean body mass from baseline to euthanasia, unlike vehicle controls, with a significant time-by-treatment interaction.

    In plain wordsIn marmosets, ACE‑031 increased lean body mass from baseline, unlike vehicle controls.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseLean body mass
    Study

    Callithrix jacchusn: not reported in source

    Common marmosets
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 14 weeksAs given in this study (Callithrix jacchus).

    Source sentences

    Summary
    There was a significant main effect of time and time x treatment interaction for lean body mass, such that marmosets administered ACE-031 were greater at euthanasia compared to baseline; this was not observed in the vehicle-treated controls.
    1 context sentence
    Summary · context
    Marmosets were randomized to receive ACE-031 or vehicle control (10 mM Tris buffered saline; TBS) for 14 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In marmosets treated with ACE‑031, biceps type I fiber cross-sectional area increased.

    In plain wordsIn marmosets, ACE‑031 increased the size of type I biceps muscle fibers.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseType I biceps fiber cross-sectional area
    Study

    Callithrix jacchusn: not reported in source

    Common marmosets
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 14 weeksAs given in this study (Callithrix jacchus).

    Source sentences

    Summary
    Biceps brachii exhibited a significant increase in the cross-sectional area of both type I and type II fibers and ex vivo contractile properties of the EDL showed an increase in absolute and specific force production.
    1 context sentence
    Summary · context
    Marmosets were randomized to receive ACE-031 or vehicle control (10 mM Tris buffered saline; TBS) for 14 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In marmosets treated with ACE‑031, biceps type II fiber cross-sectional area increased.

    In plain wordsIn marmosets, ACE‑031 increased the size of type II biceps muscle fibers.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseType II biceps fiber cross-sectional area
    Study

    Callithrix jacchusn: not reported in source

    Common marmosets
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 14 weeksAs given in this study (Callithrix jacchus).

    Source sentences

    Summary
    Biceps brachii exhibited a significant increase in the cross-sectional area of both type I and type II fibers and ex vivo contractile properties of the EDL showed an increase in absolute and specific force production.
    1 context sentence
    Summary · context
    Marmosets were randomized to receive ACE-031 or vehicle control (10 mM Tris buffered saline; TBS) for 14 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In marmosets treated with ACE‑031, terminal ex vivo EDL testing showed increased absolute force.

    In plain wordsIn marmosets, muscles tested outside the body after ACE‑031 treatment produced more absolute force.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseEDL absolute force
    Study

    Callithrix jacchusn: not reported in source

    Common marmosets
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 14 weeksAs given in this study (Callithrix jacchus).

    Source sentences

    Summary
    Biceps brachii exhibited a significant increase in the cross-sectional area of both type I and type II fibers and ex vivo contractile properties of the EDL showed an increase in absolute and specific force production.
    1 context sentence
    Summary · context
    Marmosets were randomized to receive ACE-031 or vehicle control (10 mM Tris buffered saline; TBS) for 14 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In marmosets treated with ACE‑031, terminal ex vivo EDL testing showed increased specific force.

    In plain wordsIn marmosets, muscles tested outside the body after ACE‑031 treatment produced more force relative to muscle size.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseEDL specific force
    Study

    Callithrix jacchusn: not reported in source

    Common marmosets
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 14 weeksAs given in this study (Callithrix jacchus).

    Source sentences

    Summary
    Biceps brachii exhibited a significant increase in the cross-sectional area of both type I and type II fibers and ex vivo contractile properties of the EDL showed an increase in absolute and specific force production.
    1 context sentence
    Summary · context
    Marmosets were randomized to receive ACE-031 or vehicle control (10 mM Tris buffered saline; TBS) for 14 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.